BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

UMass Boston Researcher Raises Questions on Validity and Trustworthiness of American Psychiatric Association Clinical Guidelines


3/20/2013 3:01:28 PM

(Boston, March 20, 2013) — All of the panel members that produced the American Psychiatric Association (APA)’s Practice Guideline for the Treatment of Patients with Major Depressive Disorder had numerous financial ties to drug companies that manufacture antidepressants, raising questions about the trustworthiness of the guideline, a UMass Boston researcher says.

Lead investigator Lisa Cosgrove and her research team evaluated the quality of the evidence to support antidepressant medication. The APA recommends pharmacotherapy as a first-line of intervention for all levels of depression, but Cosgrove’s new study published in the Journal of Evaluation in Clinical Practice found that 34.2 percent of the cited research did not study outpatients with major depressive disorder, and 17.2 percent did not measure clinically relevant results.

“The recommendation for antidepressants for mild depression is not congruent with the evidence. Other guidelines such as those produced by the National Institute for Clinical Excellence explicitly state antidepressants should not be first-line intervention for mild depression,” she said. “Recent Dutch guidelines recommend antidepressants as first-line treatment only in cases of severe depression. People may be exposed to unnecessary harm.”

Cosgrove, associate professor of counseling and school psychology at UMass Boston and a research lab fellow at Harvard University’s Edmond J. Safra Center for Ethics, and her fellow researchers found that all of the committee members reported ties to the financial industry. The number of relationships ranged from 9 to 33; the mean was 20.5. Cosgrove said that number should be zero.

Researchers also found that the majority of the committee participated on pharmaceutical companies’ speakers’ bureaus and the independent panel had undeclared financial relationships. Doctors serving on a speakers bureau are referred to as a “Key Opinion Leaders” or “KoLs” because they are so important to the marketing of a drug.

Cosgrove and her colleagues say it is critical that the groups developing clinical practice guidelines (CPGs) pay attention to the quality of cited studies as well as the bias resulting from conflicts of interest so as to not put patients at risk. About UMass Boston

With a growing reputation for innovative research addressing complex issues, the University of Massachusetts Boston, metropolitan Boston’s only public university, offers its diverse student population both an intimate learning environment and the rich experience of a great American city. UMass Boston’s nine colleges and graduate schools serve nearly 16,000 students while engaging local, national, and international constituents through academic programs, research centers, and public service activities. To learn more about UMass Boston, visit www.umb.edu.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES